Mathews Journal of Pharmaceutical Science

Dr. Latha Kiran Krishna Rajendran

MBBS | General Practitioner | Clinical Researcher | Author | Innovator
Elova Hospitals
India

Dr. Latha Kiran Krishna Rajendran MBBS | General Practitioner | Clinical Researcher | Author | Innovator Elova Hospitals, India Dr. Latha Kiran Krishna Rajendran is a physician, clinical researcher, author, inventor, and international keynote speaker with more than seven years of experience spanning clinical medicine, public health, preventive healthcare, emergency medicine, women's health, and translational medical research. She earned her Bachelor of Medicine and Bachelor of Surgery (MBBS) degree from Vydehi Institute of Medical Sciences and Research Centre, Bengaluru, India, and has since built a career that bridges frontline patient care with cutting-edge biomedical innovation. Currently serving as a General Practitioner and Consultant at Elova Hospitals, Dr. Rajendran manages a high-volume outpatient practice, providing comprehensive care across a wide spectrum of acute and chronic medical conditions. Her clinical expertise encompasses primary care, chronic disease management, maternal and child health, preventive medicine, emergency stabilization, geriatric care, and healthcare quality improvement. Through her commitment to evidence-based medicine and patient-centered care, she has positively impacted the lives of thousands of patients while contributing to the advancement of healthcare delivery. Prior to joining Elova Hospitals, Dr. Rajendran served as a Medical Officer with Karuna Trust at Adugodi Urban Primary Health Centre, Bengaluru. In this leadership role, she actively contributed to large-scale public health initiatives, infectious disease management, immunization programs, maternal healthcare services, and chronic disease control. During the COVID-19 pandemic, she played a vital frontline role in disease surveillance, patient management, diagnostic services, and vaccination campaigns, contributing significantly to community healthcare and public health resilience. Alongside her clinical responsibilities, Dr. Rajendran has established a distinguished academic profile through her interdisciplinary research at the convergence of oncology, artificial intelligence, precision medicine, predictive analytics, digital health, and translational biomedical sciences. She has authored multiple peer-reviewed publications in Scopus-indexed journals addressing critical challenges in cancer diagnosis, immunotherapy, nanomedicine, theranostics, genomic profiling, pharmacogenomics, machine learning-driven clinical decision support, predictive oncology, and personalized treatment strategies. Her research portfolio further includes innovative work in early cancer detection, computational medical imaging, disease modeling, omics-driven patient stratification, and AI-enabled predictive healthcare systems. A published author and healthcare innovator, Dr. Rajendran has written multiple scholarly books focused on precision oncology, cancer immunotherapy, genomic medicine, theranostics, and emerging biomedical technologies. She is also an inventor with several utility patents centered on artificial intelligence applications in oncology, precision therapeutics, immunotherapy optimization, and advanced healthcare technologies. Recognized internationally for her scholarly contributions, Dr. Rajendran serves as a peer reviewer for scientific journals and international conferences and has contributed to the advancement of research quality through rigorous academic evaluation. She has also served as a Session Chair, Invited Speaker, and International Keynote Speaker at ieee , springer conferences, presenting on artificial intelligence in healthcare, predictive oncology, precision medicine, digital twins, and next-generation cancer care. Through her combined achievements as a Clinician, Researcher, Author, Inventor, Reviewer, and Speaker, Dr. Rajendran remains dedicated to advancing predictive, personalized, and technology-driven healthcare while shaping the future of precision oncology and translational medicine.